全文获取类型
收费全文 | 13912篇 |
免费 | 614篇 |
国内免费 | 99篇 |
专业分类
耳鼻咽喉 | 231篇 |
儿科学 | 287篇 |
妇产科学 | 194篇 |
基础医学 | 1972篇 |
口腔科学 | 184篇 |
临床医学 | 795篇 |
内科学 | 3687篇 |
皮肤病学 | 212篇 |
神经病学 | 846篇 |
特种医学 | 427篇 |
外科学 | 2282篇 |
综合类 | 93篇 |
一般理论 | 1篇 |
预防医学 | 423篇 |
眼科学 | 134篇 |
药学 | 894篇 |
中国医学 | 30篇 |
肿瘤学 | 1933篇 |
出版年
2023年 | 64篇 |
2022年 | 121篇 |
2021年 | 278篇 |
2020年 | 145篇 |
2019年 | 175篇 |
2018年 | 247篇 |
2017年 | 201篇 |
2016年 | 234篇 |
2015年 | 255篇 |
2014年 | 368篇 |
2013年 | 441篇 |
2012年 | 735篇 |
2011年 | 825篇 |
2010年 | 480篇 |
2009年 | 406篇 |
2008年 | 684篇 |
2007年 | 783篇 |
2006年 | 822篇 |
2005年 | 844篇 |
2004年 | 822篇 |
2003年 | 818篇 |
2002年 | 863篇 |
2001年 | 361篇 |
2000年 | 330篇 |
1999年 | 342篇 |
1998年 | 208篇 |
1997年 | 204篇 |
1996年 | 158篇 |
1995年 | 117篇 |
1994年 | 151篇 |
1993年 | 137篇 |
1992年 | 220篇 |
1991年 | 195篇 |
1990年 | 181篇 |
1989年 | 173篇 |
1988年 | 144篇 |
1987年 | 144篇 |
1986年 | 139篇 |
1985年 | 105篇 |
1984年 | 91篇 |
1983年 | 68篇 |
1982年 | 52篇 |
1981年 | 37篇 |
1980年 | 46篇 |
1979年 | 50篇 |
1978年 | 44篇 |
1977年 | 37篇 |
1973年 | 32篇 |
1970年 | 27篇 |
1969年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
Hori Hiroki Ohta Asuka Matsui Honami Yano Kanako Morita-Tominaka Miyuki Linn Zayar Masumoto Daisuke Okumura Yosuke Okamura Satoshi Kurihara Kosuke Hayakawa Akira Rikiishi Takeshi Kobayashi Kyoko 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(1):245-252
International Journal of Clinical Oncology - The practice of cancer diagnosis disclosure to children has been changed with the times. The regulations of clinical trials in the 2000s might change... 相似文献
2.
3.
4.
5.
6.
7.
Shiro Akinaga Tadashi Ashizawa Katsushige Gomi Hiroe Ohno Makoto Morimoto Chikara Murakata Masami Okabe 《Cancer chemotherapy and pharmacology》1992,29(4):266-272
Summary Novel derivatives of K-252a, (8R*,9S*,11S*)-(–)-9-hydroxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro-8, 11-epoxy-1H,8H,11H-2,7b,11a-triazadibenzo [a,g]-cycloocta[cde]trinden-1-one, an inhibitor of protein kinases and calmodulin-dependent phosphodiesterase, were synthesized and evaluated for their antitumor activity in vitro and in vivo. Of ten derivatives tested, four were active against the P388 murine leukemia i. p.-i. p. system, although K-252a was inactive. Among these derivatives, KT6124 was selected for further biological evaluation studies because its efficacy was the highest. KT6124 was also active against sarcoma 180 and B16 melanoma. It exerted a relatively broad spectrum of antiproliferative activity against 20 human tumor cell lines in vitro. To determine the mechanism(s) of action underlying the antitumor activity of KT6124, we tested the drug for inhibition of protein kinases, including Ca2+-and phospholipid-dependent protein kinase (PKC), in intact A431 human epidermoid carcinoma cells in comparison with the PKC-inhibitory activity of K-252a. KT6124 did not antagonize the action of phorbol 12-myristate 13-acetate (PMA) in A431 cells, whereas K-252a did, suggesting that KT6124 may not act on protein kinases in the cells. The interaction of KT6124 with DNA in living cells was examined by the alkaline elution method. KT6124 apparantly exhibited DNA scission both dose-and time-dependently in the target cells. The DNA breakage was dependent on proteinase K treatment, suggesting its possible interaction with DNA-related enzyme(s). These results indicate that KT6124 exerts antitumor activity by acting on DNA or on DNA-related enzyme(s) in tumor cells rather than via the inhibition of protein kinases. 相似文献
8.
E Nakano T Yoshioka M Matsuda T Sonoda H Yano Y Ihara H Kuroda T Kishimoto T Sakurai K Uchida 《Hinyokika kiyo. Acta urologica Japonica》1990,36(5):635-642
Clinical effect of LM-001, a prostaglandin synthetic inhibitor developed from a drug delivery system, was evaluated in 54 patients with pain from urinary tract stones (stone pain) and 32 with vesical urgency after an operation on bladder or prostate. LM-001, felbinac ethyl incorporated in lipid microsphere, wes intravenously administered at the onset of stone pain or vesical urgency. Of 54 with stones and 32 with urgency, 53 and 29 were eligible for response, respectively. The symptoms improved or disappeared in some cases just after the administration and in the majority of patients within 15 minutes, in 49 of 53 patients with stone pain. Further, the effectiveness lasted over 24 hours in 26 of the 49 responding to this agent. On one hand, improvement or disappearance of vesical urgency was recognized in 25 of 29 patients, and the effectiveness was observed shortly after injection in 16 and lasted over 24 hours in 13 cases. Toxicities of this drug were investigated in 54 patients with stone pain and 32 with urinary urgency. Side effects consisted of pain at the injection site in 4, a slight fall of blood pressure in 1, slight visual disturbance in 1, body heat sensation in 1, leukocytosis in 3 and elevation of alkaline phosphatase in 1. These symptoms were transient and disappeared without use of any agent. LM-001 is concluded to be a useful drug for controlling stone pain and vesical urgency since an immediate effect, long durability and high response rates were obtained without severe side 相似文献
9.
Preoperative concurrent chemotherapy and radiation therapy followed by surgery for esophageal cancer. 总被引:1,自引:0,他引:1
Masahiko Yano Masatoshi Inoue Hitoshi Shiozaki 《Annals of thoracic and cardiovascular surgery》2002,8(3):123-130
Currently, the most promising strategy to improve the prognosis of advanced esophageal cancer is preoperative chemoradiation (CRT) followed by surgery. The superiority of CRT over radiation therapy alone has been demonstrated by several randomized studies. Many phase II studies of CRT followed by surgery have shown that the pathologic complete response (CR) rate ranges from 17 to 40%, and the median survival time (MST) is 12 to 31.3 months. Five randomized trials have compared preoperative CRT followed by surgery with surgery alone for resectable esophageal cancer, and four of them did not find any significant survival benefit for the combined treatment group. There are several issues in interpreting these findings, such as the quality of the surgery, the accuracy of the preoperative staging, the statistical power and design of the trials. Until comprehensive evaluation can be done, the standard therapy for resectable esophageal cancer should be considered to be surgery alone. The histological response in the resected specimen correlates well with the prognosis. Patients with pathologic CR display significantly better survival than those with microscopic residual cancer cells in the resected specimens. These findings suggest that more potent regimens leading to higher pathologic CR rates should improve the prognosis. Chemotherapy or radiation therapy sensitivity testing needs to be established. If accurate prediction of the response is possible prior to therapy, non-responders can be excluded. Cell cycle-related genes, apoptosis-related genes, and drug metabolizing genes have been investigated in many pilot studies and need to be evaluated by large-scale clinical studies. At present, pathologic CR can not be accurately diagnosed before surgery. Endoscopic biopsy is also unreliable for the diagnosis. In the future, new diagnostic tools such as positron emission tomography scanning, a sensitivity test or molecular markers may enable accurate diagnosis of pathologic CR to guide the choice of treatment strategies for individual patients. 相似文献
10.
Tadashi Teshirogi M.D. Hiroeki Hosoi M.D. Yukashi Ohki M.D. Toshio Kagoshima M.D. 《Pediatrics international》1987,29(3):335-339
Residual pancreatic B-cell function was investigated in children with diabetes mellitus in whom classification of the type of disease was difficult at the first visit. Intravenous glucagon tests were performed at the first visit and subsequently, the C-peptide responses compared. Based on our data on a limited number of patients, we propose C-peptide concentrations of 3.0 to 3.5 ng/ml at the peak or at 6 min after injection of glucagon, as the critical level which distinguishes non-insulin dependent from insulin-dependent diabetes mellitus. However, the degree of obesity, clinical stage and other factors also need to be considered in the classification of diabetes mellitus. 相似文献